Calibration-free NGS quantitation of mutations below 0.01% VAF
暂无分享,去创建一个
Peng Dai | Lucia Wu | Sherry Chen | Michael Wang | Lauren Chen | Jinny Zhang | Christina Hao | Weijie Yao | Jabra Zarka | Ghayas Issa | Lawrence Kwong | David Zhang | L. Kwong | J. Zhang | L. Wu | D. Zhang | Pengying Hao | Weijie Yao | L. Y. Cheng | P. Dai | M. Wang | G. Issa | S. Chen | Jabra Zarka | L. Cheng
[1] B. Gruhn,et al. Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders , 2020, Leukemia.
[2] Kari Stefansson,et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. , 2017, Blood.
[3] J. Jorgensen,et al. How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia? , 2017, Clinics in laboratory medicine.
[4] M. McCarthy,et al. Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.
[5] T. Druley,et al. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults , 2016, Nature Communications.
[6] J. Ptak,et al. Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands , 2021, Nature Biotechnology.
[7] D. Berry,et al. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. , 2020, JAMA oncology.
[8] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[9] Yashma Patel,et al. Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.
[10] S. Gabriel,et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.
[11] Behzad Baradaran,et al. The Different Mechanisms of Cancer Drug Resistance: A Brief Review , 2017, Advanced pharmaceutical bulletin.
[12] P. A. Futreal,et al. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Quince,et al. Insight into biases and sequencing errors for amplicon sequencing with the Illumina MiSeq platform , 2015, Nucleic acids research.
[14] H. Kantarjian,et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring , 2014, Haematologica.
[15] Markus G. Manz,et al. Molecular Minimal Residual Disease in Acute Myeloid Leukemia , 2018, The New England journal of medicine.
[16] R. DeSalle,et al. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance , 2016, Oncotarget.
[17] Vladimir Potapov,et al. Examining Sources of Error in PCR by Single-Molecule Sequencing , 2017, PloS one.
[18] K. Kinzler,et al. Detection and quantification of rare mutations with massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.
[19] M. Dubé,et al. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. , 2017, Blood.
[20] K. Lewis. Persister cells, dormancy and infectious disease , 2007, Nature Reviews Microbiology.
[21] Jesse J. Salk,et al. Detection of ultra-rare mutations by next-generation sequencing , 2012, Proceedings of the National Academy of Sciences.
[22] Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics , 2020, Nature communications.
[23] Endre Kiss,et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease , 2018, Nature Communications.
[24] Verena I Gaidzik,et al. Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation , 2019, Nature Communications.
[25] M. Stratton,et al. Somatic mutation landscapes at single-molecule resolution , 2021, Nature.
[26] James D. Brenton,et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.
[27] Klaus Pantel,et al. Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.
[28] T. Kunkel,et al. DNA polymerase fidelity and the polymerase chain reaction. , 1991, PCR methods and applications.
[29] L. Shlush. Age-related clonal hematopoiesis. , 2018, Blood.
[30] Umer Zeeshan Ijaz,et al. Illumina error profiles: resolving fine-scale variation in metagenomic sequencing data , 2016, BMC Bioinformatics.
[31] J. Jorgensen,et al. Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future , 2014, Bone Marrow Transplantation.
[32] Yalei Wu,et al. Multiplexed enrichment of rare DNA variants via sequence-selective and temperature-robust amplification , 2017, Nature Biomedical Engineering.
[33] Marc Lipsitch,et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug resistant tuberculosis , 2013, Nature Genetics.
[34] Ash A. Alizadeh,et al. Integrated digital error suppression for improved detection of circulating tumor DNA , 2016, Nature Biotechnology.
[35] A. Shaw,et al. Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.